Pharma Exporters

Indian pharmaceutical exports stood at nearly USD 29 billion up to February this financial year registering a growth of five per cent compared to the same period last year, a top official said on Saturday. K Raja Bhanu, Director General, Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) said the sector, currently valued at approximately USD 60 billion, is projected to grow to USD 130 billion by 2030. "Inspite of global challenges, pharmaceuticals exports have been one of the few sectors that has maintained its growth momentum. Pharmaceutical exports during the period AprilFebruary FY26 stood at USD 28.29 billion, reflecting a growth of 5.6 per cent compared to the same period in FY25 led by formulations, biologicals, vaccines and Ayush products," he said. The official further said the exports reached USD 30.47 billion in FY 202425, reflecting a growth of 9.4 percent year on year despite global pricing pressures and trade volatilities..

India's pharma exports saw a significant rise in March, driven by fears of impending US tariffs. Industry experts anticipate impact of potential reciprocal tariffs on India's future export strategy

President Trump has said tariffs on pharmaceutical and semiconductor imports will be announced shortly, as the US imposes a 27% duty on all imports from India

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator to market its generic Loteprednol Etabonate ophthalmic suspension indicated for temporary relief of seasonal allergic conjunctivitis. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Loteprednol Etabonate ophthalmic suspension, 0.2 per cent, Lupin said in a regulatory filing. It is a generic equivalent to the reference listed drug (RLD) Alrex ophthalmic suspension, 0.2 per cent of Bausch & Lomb Inc. The product will be manufactured at Lupin's Pithampur facility in India, the company added. Loteprednol Etabonate ophthalmic suspension, 0.2 per cent, is indicated for the temporary relief of signs and symptoms of seasonal allergic conjunctivitis. It had estimated annual sales of USD 29.1 million in the US market, Lupin said citing IQVIA MAT October 2023 data.

The exports in 2021-22 sustained a positive growth despite the global trade disruptions and drop in demand for COVID related medicines

As uncertainty looms large in Afghanistan, Indian pharma exporters are apprehensive to send goods to the war-torn country

Ipca's first half performance holds testimony to its robust growth with India business growing in mid-teens

Oil-exporting nations facing payment pressure on low crude oil prices